The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Explore the breadth of our life sciences degrees, spanning the full breadth of life sciences from molecules through to ecosystems. Learn more about the expertise of our research labs where we deliver ...

She then transitioned into business roles within healthcare. Before arriving at Gilead Sciences in 2021, she worked at Bio-Rad Laboratories and in client services and digital strategy at Giant ...

Kevin Cramer, founder, CEO, and CTO of Sapio Sciences, commented: “Sapio’s mission is to accelerate discovery by simplifying the complexities of science, and the new capabilities in Release 24 ...

Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit. Kite has agreed to acquire all ...

All you need to do is bring your sense of wonder and a readiness to make a positive impact in the health and medical sciences. RIT is a Leader in Pass Rates for National Health Care and Medical ...

The most recent trading session ended with Gilead Sciences (GILD) standing at $91.41, reflecting a -0.51% shift from the previouse trading day's closing. The stock's performance was behind the S&P ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other dividend stocks. Macroeconomic factors have weighed on US stocks in the final ...